Findings showed patients treated with efgartigimod alfa–hyaluronidase achieved a statistically significant improvement in MGII PRO ocular scores vs placebo at week 4. Topline data were announced from ...

(ENXTBR:ARGX) plans to present new Phase 3 data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology ...

Efgartigimod (Vyvgart, argenx) led to statistically significant improvements in symptoms of ocular myasthenia gravis (MG) in the phase 3 ADAPT OCULUS trial, according to topline results released by ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Already on a roll with its first-in-class FcRn blocker Vyvgart, argenx has reported successful trial results that could pave the way for the fast-rising blockbuster to reach a new indication—ocular ...

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. argenx (ENXTBR:ARGX) reported positive topline data from its Phase 3 ADAPT OCULUS ...

argenX recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nicholas Silvestri ...

First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S.